Crossmark

ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?

Published Online: 2021-01-21

Published Print: 2021-08

Authors

Kangas-Dick, Aaron https://orcid.org/0000-0003-1264-2054
Berger, Adam C.

Koshenkov, Vadim
License Information

Text and Data Mining valid from 2021-01-21

Version of Record valid from 2021-01-21
More Information

Article History

Received: 4 January 2021

Accepted: 5 January 2021

First Online: 21 January 2021

Disclosures

: Melanoma Decision Dx is a genetic assay developed by a company called Castle Biosciences. The manuscript assesses the effectiveness of the assay in predicting recurrence of melanoma. Vadim Koshenkov has sat on advisory boards of Castle Biosciences that discussed the application of the assay with other physicians. Aaron Kangas-Dick and Adam C. Berger have no disclosures to declare.

Document is current